Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,253 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo First Clear all
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

NCT05392192
View directory record Official record
Conditions
Chronic Cough
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

NCT03244644
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 18, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

NCT02204371
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 18, 2026, 5:32 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Povidone Iodine for Caries Prevention

NCT07741409
View directory record Official record
Conditions
Dental Caries
Interventions
Povidone Iodine 5% Soln,Top,Kit, Probiotics, Placebo
Drug · Dietary Supplement
Lead sponsor
Jeffrey A. Banas
Other
Eligibility
1 Year to 3 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 18, 2026, 5:32 AM EDT
Recruiting Phase 4 Interventional

Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis

NCT06245109
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Duloxetine, Celecoxib, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
41 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 18, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional Results available

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

NCT04963270
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Satralizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

An Implantable Microneuromodulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects

NCT00567541
View directory record Official record
Conditions
Shoulder Pain Chronic
Interventions
Battery Powered Microneuromodulator (BBPM)
Device
Lead sponsor
Bioness Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Downey, California • Seattle, Washington • Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Functional Dyspepsia Treatment Trial

NCT00248651
View directory record Official record
Conditions
Dyspepsia and Other Specified Disorders of Function of Stomach
Interventions
Amitriptyline, Escitalopram, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 18, 2026, 5:32 AM EDT
Withdrawn Phase 2 Interventional

Topical Crisaborole in Patients with Alopecia Areata

NCT04299503
View directory record Official record
Conditions
Alopecia Areata
Interventions
Crisaborole Topical Ointment, Placebo Topical Ointment
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 18, 2026, 5:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aromatherapy With Lavender as Anxiolysis Prior to Cataracts Surgery

NCT05708066
View directory record Official record
Conditions
Aromatherapy, Anxiety
Interventions
Lavender Aromatherapy, Non-scented Tab
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 18, 2026, 5:32 AM EDT
Terminated Not applicable Interventional

Efficacy of a Mechanical Chair for Treatment of Benign Paroxysmal Positional Vertigo (BPPV)

NCT03161470
View directory record Official record
Conditions
Vertigo, Benign Paroxysmal Positional Vertigo
Interventions
Standard Repositioning, Mechanical Chair Repositioning, Sham Treatment
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 18, 2026, 5:32 AM EDT
Recruiting Phase 2Phase 3 Interventional

Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children

NCT04724252
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-722, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome

NCT04541589
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Iscalimab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Suwanee, Georgia • Baton Rouge, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 18, 2026, 5:32 AM EDT
Not yet recruiting Phase 2 Interventional

Study of Psilocybin Under Anesthesia Controlled by EEG

NCT07479550
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin (Usona Institute), Propofol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 5:32 AM EDT
Terminated Not applicable Interventional Results available

Caffeine to Reduce Mechanical Ventilation in Preterm Infants

NCT01751724
View directory record Official record
Conditions
Prematurity, Apnea, Respiratory Failure
Interventions
Caffeine citrate, Normal saline
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
1 Day to 5 Days
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults

NCT02788188
View directory record Official record
Conditions
Middle East Respiratory Syndrome Coronavirus
Interventions
SAB-301, Normal (9%) Saline
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

NCT04668066
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-07242813, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Anaheim, California • Fountain Valley, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management

NCT00679302
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Trimethoprim-sulfamethoxazole, Placebo group
Drug
Lead sponsor
St. Louis University
Other
Eligibility
3 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 18, 2026, 5:32 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Alcohol and Bariatric Surgery

NCT02766322
View directory record Official record
Conditions
Obesity
Interventions
Oral Alcohol challenge test Alcohol visit first, Oral Alcohol challenge test Placebo visit first, Intravenous Alcohol Challenge Test (Clamp), Intravenous Alcohol Self-administration Test
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 18, 2026, 5:32 AM EDT
Recruiting Early Phase 1 Interventional

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

NCT05921253
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
PARASYM neuromodulation device
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder

NCT03418623
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
GET73, Placebo
Drug · Other
Lead sponsor
Laboratorio Farmaceutico Ct S.r.l.
Industry
Eligibility
21 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 18, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

NCT00305188
View directory record Official record
Conditions
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
Interventions
Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 18, 2026, 5:32 AM EDT